BCL2L10 Is a non-GCB-associated prognostic biomarker and functional driver in diffuse large B-Cell lymphoma
Biochemical and Biophysical Research Communications · 2026-08 · 827 · 154000
DOI: 10.1016/j.bbrc.2026.154000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026-08. Verfasst von Lili Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, PR China; Department of Medical Oncology, Lanzhou University Second Hospital,…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Biomarkers, Tumor, Proto-Oncogene Proteins c-bcl-2. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Gansu Provincial Natural Science Foundation.
Abstract (Originalsprache)
Diffuse large B-cell lymphoma (DLBCL) is characterized by marked heterogeneity between GCB and non-GCB subtypes. Here, we identified BCL2L10 as a non-GCB-specific oncogene through integrated bioinformatics, clinical validation, and functional assays. BCL2L10 was significantly upregulated in non-GCB DLBCL at both mRNA and protein levels. High BCL2L10 expression served as an independent adverse prognostic factor and correlated with advanced clinical stage. Gene set enrichment analysis linked BCL2L10 to biosynthetic and stress-response pathways. Functional assays demonstrated that BCL2L10 knockdown selectively suppressed proliferation in non-GCB DLBCL cells, whereas overexpression only mildly promoted GCB cell growth. Our findings identify BCL2L10 as a novel subtype-specific prognostic biomarker and therapeutic target for high-risk non-GCB DLBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, PR China; Department of Medical Oncology, Lanzhou University Second Hospital, Lanzhou, Gansu, PR China.
- Department of Clinical Laboratory, The First Hospital of Lanzhou University, Lanzhou, Gansu, PR China.
- Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu, PR China.
- Obstetrics and Gynecology Intensive Care Center/MICU, Gansu Provincial Maternity and Child-care Hospital, Lanzhou, Gansu, PR China.
- Harrison International Peace Hospital, Hengshui, Hebei, PR China.
- Department of Medical Oncology, Lanzhou University Second Hospital, Lanzhou, Gansu, PR China.
Förderung
- Gansu Provincial Natural Science Foundation
Zitieren
APA
Yu, L., Wu, S., Li, L., Yang, J., Man, J., Song, F., & Zhao, L. (2026). BCL2L10 Is a non-GCB-associated prognostic biomarker and functional driver in diffuse large B-Cell lymphoma. Biochemical and Biophysical Research Communications, 827, 154000. https://doi.org/10.1016/j.bbrc.2026.154000
Vancouver
Yu L, Wu S, Li L, Yang J, Man J, Song F, et al. BCL2L10 Is a non-GCB-associated prognostic biomarker and functional driver in diffuse large B-Cell lymphoma. Biochemical and Biophysical Research Communications. 2026;827:154000. doi:10.1016/j.bbrc.2026.154000
BibTeX
@article{Yu2026,
author = {Yu, Lili and Wu, Shiwen and Li, Liangliang and Yang, Jincai and Man, Jiancheng and Song, Feixue and Zhao, Li},
title = {BCL2L10 Is a non-GCB-associated prognostic biomarker and functional driver in diffuse large B-Cell lymphoma},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
volume = {827},
pages = {154000},
doi = {10.1016/j.bbrc.2026.154000}
}
EUVIMED